Company intelligence / Profile preview
PDC*line Pharma
Liège, Belgiumpdc-line-pharma.com ↗
- Ownership
- Private
- Employees
- ~41
- Development stage
- Other
01
Overview
Reported promising Phase I/II results in lung cancer (PDClung) in 2024. PDClung01, in combination with pembrolizumab, demonstrated potential to provide meaningful clinical benefit compared to standard treatment. Preparations underway for a randomized Phase II trial in lung cancer and a Phase Ib trial in colorectal cancer with neoantigens.
- Therapeutic areas
- Oncology
- Modalities
- Cell-based immunotherapytherapeutic cancer vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
LG Chem Life Science (licensing deal for Asia)
Beyond the preview
Go deeper on PDC*line Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDC*line Pharma.